COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00606814
Recruitment Status : Completed
First Posted : February 5, 2008
Last Update Posted : March 6, 2012
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.

Brief Summary:

This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine:

  • the safety profile,
  • the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and
  • to recommend a Phase II dose of the combination in patients with solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: IPI-504, docetaxel Phase 1

Detailed Description:

IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in maintaining the proper folding, function and viability of various "client proteins". Many of the client proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival.

This is a multi-center, open-label, dose escalating study in which patients will be treated with a fixed dose of docetaxel followed by IPI-504 following one of three dosing schedules.

Once an MTD has been defined, up to 20 additional patients with non-small cell lung cancer (NSCLC) will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
Study Start Date : December 2007
Actual Primary Completion Date : May 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Intervention Details:
  • Drug: IPI-504, docetaxel
    1. IPI-504 administered IV at a dose of 300mg/m2
    2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration
    Other Name: Taxotere

Primary Outcome Measures :
  1. To determine the safety, maximum tolerated dose(MTD)of IPI-504 in combination with docetaxel in patients with advanced solid tumors and recommend the Phase II dose of the combination of drugs. [ Time Frame: Weekly ]

Secondary Outcome Measures :
  1. To determine the pharmacokinetics (PK) and response rate (CR+PR) for patients with measurable lesions (as determine by RECIST) [ Time Frame: Weekly ]
  2. To determine the pharmacokinetics (PK) of IPI-504 and docetaxel [ Time Frame: Weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed malignancy that is metastatic or unresectable, for which one of the two statements must apply:

    • Standard therapy able to provide clinical benefit does not exist or is no longer effective AND / OR
    • Single agent docetaxel would be appropriate therapy.
  • Progressive disease with development of new lesions or an increase in preexisting lesions on CT, MRI, PET, bone scintigraphy, or by physical examination.
  • Measurable disease by RECIST criteria with the exception of prostate cancer patients.
  • >18 years of age at the time of signing the Informed Consent Form (ICF) and have a life expectancy of at least 3 months.
  • Karnofsky performance status of 70 or better.
  • Adhere to the study visit schedule
  • Voluntarily sign the Informed Consent Form (ICF).
  • Baseline studies completed within 30 days of first study dose.
  • Women of child-bearing potential (WCBP) defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months must have a negative serum or urine pregnancy test within 2 weeks of first study dose and prior to each additional cycle of treatment.
  • All WCBP and all sexually active male patients must agree to use adequate methods of birth control throughout the study

    ** Non-small cell lung cancer (NSCLC)enrolled in the Expansion Phase of the study must meet the following additional inclusion criteria:

  • NSCLC that meets the disease criteria described in the first three Inclusion Criteria.
  • Must have archival NSCLC tissue available for submission and analysis.

Exclusion Criteria:

  • Treatment within 1 week of the start of IPI-504 for erlotinib, and imatinib; within 2 weeks for gefitinib, and any other tyrosine kinase inhibitor (approved or investigational); within 4 weeks for any biologic therapy (antibody, vaccine, or other protein-based therapy), radiation therapy, or conventional chemotherapy; within 6 weeks for nitrosoureas or mitomycin C.
  • Radiation therapy within 2 weeks of the start of IPI-504. (Patients must have recovered from any toxicities.)
  • Concurrent radiation therapy or treatment with any other investigational agent is not permitted.
  • Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to Cycle 1, Dose 1.
  • Symptomatic peripheral neuropathy ≥ Grade 2.
  • Inadequate hematologic function defined by absolute neutrophil count (ANC) <1,500 cells/mm3, a platelet count <100,000/mm3, and a hemoglobin <9.0 g/dL (may be increased to this level with transfusion as long as there is no evidence of active bleeding).
  • Inadequate renal function defined by AST and/or ALT >1.5; total bilirubin above the upper limit of normal.
  • Inadequate renal function defined by serum creatinine >1.5 x ULN.
  • Sinus bradycardia (resting heart rate <50) secondary to intrinsic conduction system disease. Patients with sinus bradycardia secondary to pharmacologic treatment may enroll if withdrawal of the treatment results in normalization of the resting heart rate to within normal limits.
  • Baseline QTc >450 msec in males; QTc >470 msec in females, or previous history of QT prolongation while taking other medications.
  • Presence of left bundle branch block, right bundle branch block plus left anterior hemiblock, bifasicular block or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.
  • Patients who have received >450 mg/m2 of any anthracycline during prior chemotherapy must have a baseline LVEF >40%.
  • Active keratitis or keratoconjunctivitis.
  • History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
  • Presence of active infection or systemic use of antibiotics within 72 hours of treatment.
  • Untreated brain metastases. Note: Patients with a history of brain metastases are eligible as long as definitive treatment has been given and patients are clinically stable.
  • Significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study (e.g., cardiac disease such as acute coronary syndrome or unstable angina within 6 months, uncontrolled hypertension, arrhythmia requiring medication or mechanical control, cirrhotic liver disease, or other conditions).
  • Previous or current malignancies at other sites within the last 2 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
  • HIV-positive patients receiving combination antiretroviral therapy.
  • Women who are pregnant or lactating.
  • Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor.
  • Patients with prior hepatic resection or hepatic-directed therapy (e.g., chemoembolization or Theresphere).

    **Patients with non-small cell lung cancer (NSCLC)enrolled in the Expansion Phase of the study must meet the following additional exclusion criteria:

  • Prior treatment with docetaxel
  • Three or more chemotherapy regimens for metastatic disease. Note: Any number of prior treatment regimens with tyrosine kinase inhibitors is permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00606814

Layout table for location information
United States, Arizona
TGen Clinical Research in Scottsdale
Scottsdale, Arizona, United States, 85258
United States, Connecticut
Yale Cancer Center
New Haven, Connecticut, United States, 06519
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Memorial Sloan-Kettering Cancer Center
New York City, New York, United States, 10066
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
Gabrail Cancer Center
Dover, Ohio, United States, 44622
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Infinity Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Gregory Riely, MD Memorial Sloan Kettering Cancer Center
Layout table for additonal information
Responsible Party: Infinity Pharmaceuticals, Inc. Identifier: NCT00606814    
Other Study ID Numbers: IPI-504-05
First Posted: February 5, 2008    Key Record Dates
Last Update Posted: March 6, 2012
Last Verified: March 2012
Keywords provided by Infinity Pharmaceuticals, Inc.:
Solid Tumors, IPI-504, docetaxel,cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action